Navigation Links
Roxane Laboratories, Inc. Announces the Launch of Perindopril Erbumine Tablets
Date:11/10/2009

COLUMBUS, Ohio, Nov. 10 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Perindopril Erbumine Tablets, 2mg, 4mg and 8mg by the U.S. Food and Drug Administration. The product is available in bottles of 100 for immediate shipment to wholesalers and pharmacies nationwide.

Roxane Laboratories' Perindopril Erbumine Tablets are AB rated to ACEON® (perindopril erbumine) tablets. Annual sales of ACEON® are approximately $24.1 Million(1).

Full prescribing information for Perindopril Erbumine Tablets is available on the Roxane Laboratories website at www.Roxane.com or upon request by calling Roxane Laboratories Technical Product Information at

1.800.962.8364.

About Roxane Laboratories, Inc.

Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 80 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled- release tablets; nasal sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and approximately 41,300 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2008, Boehringer Ingelheim posted net sales of US $17 billion (11.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information on Boehringer Ingelheim, please visit http://us.boehringer-ingelheim.com.

(1) IMS MAT dollar sales ending 9/2009

ACEON® is a registered trademark of Solvay Pharmaceuticals, Inc.

SOURCE Roxane Laboratories, Inc.


'/>"/>
SOURCE Roxane Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Roxane Laboratories, Inc. Announces the Launch of Risperidone Oral Solution 1mg/mL
2. Roxane Laboratories, Inc. Announces the Launch of Levetiracetam Tablets and Oral Solution
3. Roxane Laboratories, Inc. Initiates a Nationwide Voluntary Recall of Two Manufacturing Lots of Sodium Polystyrene Sulfonate Suspension in the US and Puerto Rico
4. Roxane Laboratories, Inc. Announces the Approval of Morphine Sulfate Tablets and Oral Solution
5. Roxane Laboratories, Inc. Announces the Launch of Ramipril Capsules
6. Roxane Laboratories, Inc. Announces the Launch of Acarbose Tablets
7. Roxane Laboratories, Inc. Announces the Launch of Granisetron Hydrochloride Tablets, 1mg
8. Roxane Laboratories, Inc. Announces the Launch of Balsalazide Disodium Capsules, 750mg
9. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
10. Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation of Georges Ugeux from Board of Directors
11. Caraco Pharmaceutical Laboratories, Ltd. Announces Appointment of F. Folsom Bell to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... Beach, CA (PRWEB) , ... May 23, 2017 ... ... Certified Facial Plastic and Reconstructive Surgeon Dr. Kevin Sadati, is pleased to announce ... interested in building collagen and elastin in their face, neck, and body through ...
(Date:5/23/2017)... ... May 23, 2017 , ... MedTech ... in the modern ART laboratory, to provide hands-on training utilizing cutting-edge equipment at ... NextGen LifeLabs, a MedTech Group Purchasing vendor , will provide specialized equipment ...
(Date:5/23/2017)... ... May 23, 2017 , ... Orbita’s Nathan Treloar will discuss the role of ... Francisco. Titled Connected Health and IoT: Technology Innovators and Disruption , the workshop ... Associates, a market research and consulting firm specializing in emerging consumer technology products and ...
(Date:5/23/2017)... ... ... Therachat , a smart guided journaling tool for improving mental health, ... of anxiety in support of National Mental Health Awareness Month. , The nationwide survey ... general anxiety levels as well as identified the top triggers, impact to regular activities ...
(Date:5/22/2017)... ... 2017 , ... Patients who avoid necessary dental and endodontic treatments because of ... NY from Advanced Endodontics of Westchester. This highly-trained team of endodontists offer three different ... sedation methods may be recommended based on the severity of the anxiety experienced by ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... 2017  Amy Baxter MD, chief executive officer and ... pain relief, was awarded a 2017 Top 40 Healthcare ... recognized at the MM&M Top 40 Healthcare Transformers dinner ... on May 10, 2017. The dinner followed a ... "beyond the pill."  "Innovation goes beyond invention," ...
(Date:5/10/2017)... , May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of ... is based on extensive data analysis from GHI,s hospitals ... hospitals database for the region. The GHI database covers 86% ... offering more than 130 data points for each institution in ...
(Date:5/9/2017)... , May 9, 2017  Demonstrating its ... board of directors for the Pharmaceutical Research and ... for membership. Biopharmaceutical companies will now have to ... order to be eligible to join PhRMA. ... the board is sending a clear message that ...
Breaking Medicine Technology: